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25 Expert Opinion 
26 Analysis of the genome of Pseudomonas aeruginosa has greatly intensified in recent years following 
27 the publication of the type strain PAO1 genome sequence in 2000. Phenotypically diverse and a 
28 coloniser of a large variety of natural habitats, this species is able to infect both plants and humans 
29 using the same virulence armamentarium. The genomes of 4660 P. aeruginosa are in the public 
30 domain and these have started to reveal the reasons for the species evolutionary success. For a 
31 species with a relatively large genome of about 6.3 million nucleotides coding for an estimated 5600 
32 genes the essential core genome appears surprisingly small – only 321 genes. The vast majority of P. 33 
34 aeruginosa genes are shared between a small number of isolates with approximately half found in 
35 only one isolate. This unusually high level of genetic diversity is driven by frequent horizontal gene 
36 transfer events between members of the species as well as extra-species associations that are 
37 evidenced by, for example the acquisition of antibiotic resistance genes on mobile genetic elements 
38 such as plasmids containing carbapenem resistance and even colistin resistance determinants. 
39 Perhaps thankfully in this species, although multiple drug resistance (MDR) is commonplace even in 
40 environmental isolates, extreme (XDR) and pan-drug resistances are much less common and largely 
41 restricted to a relatively small number of genetic backgrounds. These high-risk clones can be easily 
2 identified by genome sequencing and there is good potential for this to become routine so that rapid 
44 diagnostics can provide antibiotic sensitivity and even virulence potential data in a clinically useful 
45 timeframe that can minimise the untargeted, empirical use of that valuable resources - antibiotics. 
46 Genomic sequencing is now used to trace P. aeruginosa outbreaks retrospectively but technology is 
47 currently sufficiently advanced to allow real-time outbreak analyses in hospitals and other healthcare 
48 settings. Currently this is financially unviable in most settings but the near future promises declining 
49 costs for genomic sequencing and future innovations will reduce the human resource requirements 
50 of current epidemiological analyses. 
51 
52 
53 Pseudomonas aeruginosa exists almost exclusively in biofilms which provide challenges for 
54 therapeutic  intervention  due  to  the  low  metabolic  activity  of  some  cells,  the  inability  of some 
55 antibiotics to adequately penetrate the biofilm matrix and the strong attachment between biofilms 
56 and human tissue and indwelling device materials. Biofilms are also obviously also the place where 
57 intra- and inter-species gene exchange occurs allowing virulence genes and antibiotic resistance genes 
58 to move. With the current dearth in antibiotic drug discovery for gram-negative nosocomial pathogens 
59 in particular the future of antimicrobial chemotherapy will need to be supplemented by other 
Expert Review of Anti-infective Therapy Page 2 of 24 
60 
2 










3 approaches to target pathogen biofilms in humans and also perhaps in environmental reservoirs of 
4 antibiotic resistance. Controlling the diverse biofilms associated with P. aeruginosa will be challenging 
5 due to the multispecies nature of many infective biofilms however targeting the species quorum- 
7 sensing network could be a possible anti-virulence strategy. Future therapies based on depleting 
8 biofilm directly using recombinant dispersins or phage-encoded polysaccharide depolymerases could 
9 also provide additional tools to limit the spread of P. aeruginosa. The removal or reduction of P. 
10 aeruginosa from water sources or wastewater processes through photocatalysis or other low-energy 
11 disinfection processes could also offer a promising future approach to reducing the reservoir of AMR 






18 1. Introduction 
19 Pseudomonas aeruginosa is ubiquitous in many natural environments such as soils and bodies of 
20 
21 water, in addition to being a major cause of infections in humans, other animals and a cause of soft 
22 rot infections in plants. This is due to its ability to survive and even thrive under a wide range of 
23 
24 temperatures, on different nutrient sources and the species inherent and acquired virulence and 
25 
26 resistances to antibiotics, disinfectants and other antimicrobial compounds [1]. It has been classified 
27 as a major species associated with multiple antimicrobial resistance of urgent public health concern 
28 
29 by the Infectious Diseases Society of America [2], Centers for Disease Control and Prevention and the 
30 
31 World Health Organization. It is a leading cause of severe, life-threatening nosocomial human 
32 infections and the major pathogen associated with lung infections in patients with cystic fibrosis [3, 4] 
33 
34 due to the pathogens various and successful virulence mechanisms. 
35 
36 
37 1.1 Virulence 
38 
39 Damage to the bacterial host, and hence bacterial pathogenicity, is due to the action of virulence 
40 
41 factors, a multifactorial process whereby bacterially-derived molecules enable entry, replication, and 
42 persistence that may lead to tissue damage [5]. A recent review by Diggle and Whiteley [6] described 
43 
44 the major virulence systems of P. aeruginosa virulence and these are shown in Figure 2. 
45 
46 Understanding virulence in P. aeruginosa has been a key research field for decades, with many factors 
47 identified as common across infection of both humans and plants, for example toxA, plcS and gacA, 
49 as well as the phenazine pigment compound pyocyanin [7, 8]. A measure of the complexity and our 
50 
51 lack of knowledge of the gene repertoire of the species is that we cannot discern human pathogenic 
52 genotypes from those infecting plants. This isillustrated in Figure 1 by the very high genetic similarity 
54 between clinical and non-clinical (environmental) isolates and the plant isolate PA14 . Quorum sensing 
55 
56 (QS), the ability for bacteria to produce and detect signalling molecules (autoinducers) is known to 
57 
58 play an important role in virulence (Figure 3), with mutations in QS genes or specific blocking/targeting 
59 of QS molecules able to reduce virulence of P. aeruginosa [9, 10, 11], although notably, such QS 
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3 mutants are not always avirulent [10]. Siderophores are small molecular weight molecules secreted 
4 
5 by bacteria for iron-chelating, and are also responsible for regulation of virulence. Pyoverdine, a major 
6 
7 siderophore in P. aeruginosa, is itself a virulence factor and regulates at least two others factors 
8 (endotoxin A and an endoprotease) [12, 13]. Virulence factors can also be activated by 
9 
10 mechanochemical sensory systems (e.g. type-IV pili) once the P. aeruginosa cell recognises a surface 
11 
12 (for example the chp system) [14] aiding in colonisation and biofilm formation. Virulence factors can 
13 also be secreted by P. aeruginosa and packaged into outer-membrane vesicles and delivered to a 
14 
15 target host at relatively long distances [15]. 
16 
17 
18 Horizontal gene transfer (HGT), the process where genetic material is passed between different 
19 
20 bacterial cells, is the most significant driver in shaping the genome of P. aeruginosa [16]. HGT can 
21 
22 occur due to a number of intra- and even inter-species processes including conjugation, transduction 
23 and transformation. Transduction, the process by which genetic information is obtained as a 
24 
25 consequence of viral (bacteriophage) infection has long been studied in P. aeruginosa [17], considered 
26 
27 a process naturally occurring in the environment, and has even been demonstrated with ‘large’ jumbo- 
28 phage [18]. Similarly, conjugation, the process by which bacteria transfer genetic material between 
30 cells, is also well studied in P. aeruginosa [19]. Recent literature has examined the effect of conjugation 
31 
32 on antibiotic resistance [20], and how biofilm phenotype may encourage this [21]. Natural 
33 transformation in P. aeruginosa, meaning the uptake of genetic material from the environment, is less 
35 studied/observed in the literature [22], with the ability to uptake and recombine naked DNA has not 
36 
37 been proven conclusively to occur in this species [23] although numerous circumstantial pieces of 
38 evidence support this mechanism of HGT. Bacteria also have mechanisms to resist HGT. Restriction- 
40 modification (R-M) systems are a highly diverse group on enzymes that can be considered ‘bacterial 
41 
42 immunity’ by defending bacterial cells from extra-cellular DNA. It is also hypothesised that R-Ms play 
43 
44 a broader role in the bacterial cell, with a recent study demonstrating P. aeruginosa R-M systems 
45 potentially impacting virulence [24]. CRISPR-Cas is another cellular mechanism that can defend a 46 
47 bacterial cell from DNA uptake and integration by protecting against bacteriophage transduction [25]. 
48 
49 One study of CRISPR-Cas systems within 672 genomes found reduced genome size to be associated 
50 with particular CRISPR-Cas types compared to those without such a system [26], however, the wider 
51 





57 Virulence in Pseudomonas aeruginosa is largely shaped by high rates of horizontal gene transfer (HGT) 
58 
59 [29] that transfers regions of DNA between cells. Pathogenicity islands (PI) are horizontally acquired 
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3 genetic elements present in the accessory genome [16] that are frequently found in virulent clinical 
4 
5 isolates of P. aeruginosa. The first such, called PAPI-1 and PAPI-2, contain homologues of genes found 
6 
7 in other human and plant pathogens [30]. A recent study found 11 out of 21 identified GI in an ocular 
8 multi-drug resistant isolate of P. aeruginosa contained virulence genes. A recent analysis of 1,311 P. 
9 
10 aeruginosa pangenomes Freschi, Vincent [29] concluded HGT has a non-negligible effect on the 
11 
12 evolution of the bacteria, and are potentially implicated in the emergence of virulence. It has also 
13 been suggested that virulence traits in P. aeruginosa are selected for and maintained even when 
14 
15 interaction with a human host is absent, potentially driven by interaction with other eukaryotic 
16 
17 organisms in the wider environment, e.g. amoeba [22]. As greater numbers of genomes for P. 
18 aeruginosa become available, pangenome/comparative genome studies will continue shedding light 
19 
20 on the genomic diversity of virulence. 
21 
22 
23 However, there is little discussion in the literature on the control of HGT, and its impact on virulence 
24 
25 and the wider issues of P. aeruginosa in healthcare settings. This review therefore seeks to discuss 
26 
27 these considerations in the wider context of P. aeruginosa as a human pathogen with consideration 
28 of relevant original research on Pseudomonas aeruginosa pathogenicity and population structure with 
30 a strong emphasis on recent large genomic and pan-genomic studies on this very successful, diverse 
31 
32 and adaptive bacterial species. All literature searches were performed in PubMed and Web of Science 
33 in the period May 2019 – March 2020. 
35 
36 
37 1.2 Lessons from Genomics? 
38 Since the first genome sequence of a P. aeruginosa isolate (PAO1) was published in 2000 [31] the 
40 species has been the subject of many genome sequencing studies - at the time of writing 4660 
41 
42 genomes are currently in the public domain making it one of the most studied pathogen species. PAO1 
43 
44 is the most commonly used P. aeruginosa laboratory strain and the subject of ongoing international 
45 efforts to ascribe functions to its 5570 open reading frames, in a genome of 6,264,403bp, through the 46 
47 Pseudomonas Genome DB project (accessible at http://www.pseudomonas.com) [32]. P. aeruginosa 
48 
49 genomes are approximately twice the size of that of the average bacterial species with around 6.3 
50 million base pairs [31, 33]. What is clearly apparent from genomic sequencing efforts to date is that 
51 
52 the species has a very large pan-genome, the full complement of genes found in the species, with a 
53 
54 very small number of core - genes found in every isolate and an extremely large accessory genome. A 
55 2019 study [34] using genomics and analysis of gene knockouts from isolates grown under different 
56 
57 conditions calculated that the number of core essential genes to be 321, which comprises only 6.6% 
58 
59 of the P. aeruginosa genome. A study the previous year by Freschi and colleagues [29] estimated that 
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3 the core genome was only 1.2% of the pan-genome based upon genomes that they sequenced or were 
4 
5 publicly available in 2016. Both of these studies and other large genome sequencing projects describe 
6 
7 a species with a minimal essential genome (compared with other bacterial species such as S. 
8 pneumoniae and C. jejuni, which has approximately 851 and 866 core genes out of an estimated 1990 
9 
10 and 1623 genes respectively [35]). According to the Freschi study, 50.1% of unique genes are found in 
11 
12 single isolates. 
13 
14 
15 Early DNA sequencing studies suggested P. aeruginosa was divided into two main groups represented 
16 
17 by PAO1 [31] - isolated from a chronic wound in the 1950s and PA14 [36]- an isolate from a plant soft- 
18 rot infection, however recent studies show a much more complex population structure comprising at 
19 
20 least five major clades according to one genomic analysis [37] although data from a 2015 study of 
21 
22 human infection and environmental isolates not included in this analysis suggests a more complex 
23 picture [26] (Figure 1). The particularly large accessory genome of P. aeruginosa is obviously a major 
24 
25 contributor to the species versatility that allows it to exploit different environmental niches as a 
26 
27 ubiquitous organism in soil and water and also as a commensal that can on occasion cause infections 
28 in plants and animals including humans. The P. aeruginosa pan-genome contains many genes that are 
30 unique to a particular isolate and provides the species with an extremely large variety of possible 
31 
32 phenotypes [38]. 
33 
34 
35 1.3 Antibiotic Resistance 
36 
37 Although antibiotic resistance (ABR) is not considered to be a virulence factor, however, 
38 understanding ABR is essential due to the increasingly important role both play in the clinical setting 
40 [39]. In its 2013 publication “Antibiotic Resistant Threats in the United States, 2013”, CDC reported 
41 
42 51, 000 cases of P. aeruginosa infections a year. 6700 (13.1%) of these were multidrug resistant (MDR), 
43 
44 that is, untreatable with three or more antibiotic classes commonly used to treat such infections. 
45 These were found to have caused 440 deaths a year in the study period [40]. European CDC data for 46 
47 2018 show a variable rate of MDR in Europe overall, with 32.1% of P. aeruginosa isolates resistant to 
48 
49 at least one antibiotic, and 19.2% isolates resistant to two or more antibiotics [41]. This report 
50 suggests large inter-country variations for resistance across all antibiotics, with generally higher 
51 
52 resistance percentages reported in southern and eastern Europe compared to northern Europe and 
53 
54 resistance to carbapenems, the most commonly used antibiotics to treat nosocomial gram-negative 
55 infections, remains common in many EU/EEA countries. Resistance to polymyxin antibiotics (colistin 
56 
57 and polymyxin B), often referred to as the antibiotic class of last resort for gram-negative infections 
58 
59 still appears to be rare in Europe, the United States, Canada and Latin America with 0.5 – 1.1% of 
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3 isolates being resistant [42] although resistance rates were higher in China with 22.2% resistance 
4 
5 among XDR (eXtremely Drug-Resistant, ie, resistant to four or more antibiotic classes) P. aeruginosa 
6 
7 from bloodstream infections, according to a 2016 report [42, 43]. 
8 1.4 Population Structure 
9 
10 Recombination is the major mechanism driving sequence divergence in this species and this enables 
11 
12 the frequent acquisition and dissemination of both virulence and antibiotic resistance genes. The very 
13 large pan-genome and large number of genes found in only one isolate indicate a very fluid species 
14 
15 [26, 37]. Analysis of the core genome also shows a highly recombining population. Multilocus 
16 
17 sequence typing (MLST), first described in 1998 for the characterization of Neisseria meningitidis [44], 
18 has been applied to the study of all common bacterial pathogens, as well as fungal species. As the 
19 
20 method relies on DNA sequencing of specific regions of (typically) seven core metabolic / 
21 
22 housekeeping gene loci and the online deposition of sequence- and meta- data, it can be used to study 
23 pathogen epidemiology at the local, national and international level. It has also been an invaluable 
24 
25 tool for studying the evolution and global spread of antibiotic resistant and / or hyper-virulent lineages 
26 
27 of species such as Staphylococcus aureus (including methicillin-resistant [MRSA] clones) [45], 
28 Streptococcus pneumoniae [46], Escherichia coli [47] and of course Pseudomonas aeruginosa [48]. 
30 MLST has also been used to examine and compare evolutionary parameters between species. 
31 
32 Comparison of the alleles for individual species allows an estimation to be made of the ratio of 
33 recombination (R) to point mutation (M) per MLST allele or per nucleotide. Two studies using this 
35 methodology estimated that MLST loci nucleotides were changed 8.4 - 9.5 times more often by 
36 
37 recombination compared to point mutation which is much lower than the naturally transformable S. 
38 pneumoniae (50 times) and N. meningitidis (80 times), species that have epidemic population 
40 structures but are demonstrably naturally transformable [49]. However these latter two species have 
41 
42 much smaller pan-genomes presumably due to their niche adaptation to almost exclusively colonise 
43 
44 and infect mammals and have much lower numbers of prophage, plasmids and other mobile genetic 




49 In an era in which rapid, inexpensive genome sequencing is now widely available traditional MLST is 
50 rarely used and most epidemiological studies nowadays extract core-genome (cg)MLST data from 
51 
52 assembled  or  unassembled  whole  genome  sequences [50, 51] for comparison with database 
53 
54 sequences and isolate information held at, for example, the PubMLST website [50, 51, 52]. This allows 
55 the identification of multiple antibiotic resistant “high risk” clones (see below) and phylogenetic and 
56 
57 phylogeographic comparisons of users isolates with the >3300 isolates present in the P. aeruginosa 
58 
59 database. 
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5 1.5 High Risk Clones 
6 
7 In common with other pathogens with epidemic population structures, P. aeruginosa is notable for 
8 the presence of genotypes that are over-represented in samples from human disease and carriage. 
9 
10 These so-called “high risk” clones are indicative of an epidemic population structure where genotypes 
11 
12 increase in frequency through rapid transmission in hospital and other environments probably due to 
13 antibiotic selection and enhanced virulence in certain vulnerable patient populations. Clonal spread 
14 
15 of P. aeruginosa genotypes belonging to clonal complex (CCs) 111, 175, 235 and 395 are associated 
16 
17 with the global dissemination of multidrug resistant genes including metallo-beta lactamases blaVIM, 
18 IMP, SPM and NDM that confer carbapenem resistance [53, 54] (Figure 1). Carbapenemase genes are 
19 
20 much more common in high-risk clones compared to other isolates and these may also have enhanced 
21 
22 virulence – one study found isolates belonging to CC111 and 235 clones were highly virulent in 





28 1.6 Biofilm / Secretion Systems 
30 In common with many bacterial pathogens P. aeruginosa cells exist within complex microbial 
31 
32 communities known as biofilm; found at surface-liquid, surface-air and liquid-air interfaces. P. 
33 aeruginosa can thrive in biofilm due to the extracellular polymeric substances (EPS) it can produce, 
35 helping the bacteria resist desiccation, mechanical removal and the actions of antibiotics and 
36 
37 disinfectants [56]. When P. aeruginosa forms biofilm in human tissue, cells are difficult to eradicate 
38 and represent infectious foci that can lead to severe systemic disease. Polymicrobial biofilms are 
40 considered a “melting pot” for horizontal gene transfer within and between bacterial species [57], 
41 
42 recognized as important niches for MDR evolution. Isolates belonging to the two high-risk CC 111 and 
43 
44 235 described earlier have been shown to produce significantly more biofilm compared to those from 
45 non-high risk clones [58]. Numerous links between virulence and biofilm have been reported in the 46 
47 literature, with the presence of P. aeruginosa in polymicrobial increasing virulence of other bacterial 
48 
49 species [59]. For example, it is suggested that the virulence factor phenazinethe, the enzyme 
50 polyphosphate kinase (ppk) and the HD-GYP domain proteins can modulate/regulate biofilm in 
51 
52 addition to virulence [60, 61, 62]. Whilst there is still considerable work to be done to unpick the 
53 
54 relationship between P. aeruginosa, virulence, HGT and biofilm production, it is clear that 




59 1.7 Bacteriophage and HGT of virulence: friend or foe? 
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3 Bacteriophage (phage) are viruses that infect bacteria, and are considered of significant interest for 
4 
5 their antibiofilm mechanism. Once a phage enters the cell, one of two life-cycles can occur. The  lytic 
6 
7 cycle results in the destruction (or lysis) of the infected cell, preceded by transcription of the phage 
8 DNA in order to synthesise new phage. The resultant destruction of the cell releases the newly formed 
9 
10 phage into the environment to continue infection of the bacterial community. Therefore, there is 
11 
12 significant interest in the ability for phage to infect and destroy bacterial cells (and particularly those 
13 in biofilm), with numerous review articles available describing the breadth of research in this area e.g. 
14 
15 [63, 64]. 
16 
17 
18 However, some phage follow the second life cycle, known as the lysogenic cycle. Here, following 
19 
20 infection, the phage DNA integrates with the bacterial DNA by a process known as transduction (a 
21 
22 form of HGT), whilst the bacterial cell continues its usual lifestyle and remains able to reproduce. This 
23 DNA, known as a mobile genetic element (MGE), can also carry genes that may increase a bacterial 
24 
25 cells ability to survive, including virulence factors and antimicrobial resistance mechanisms. MGE, 
26 
27 from phage and other sources, are well documented as an important avenue of evolution in P. 
28 aeruginosa e.g. [65, 66, 67]. One large genomic study suggests that the presence in a P. aeruginosa 
30 genome of phage transduction - targeting CRISPR-Cas sytems is associated with reduced antibiotic 
31 
32 resistance [26]. Therefore, understanding this process and targeting the mobile genetic elements of 




38 2. Control Strategies 
40 
41 
42 2.1 Antibiofilm approaches 
43 
44 As described above, P. aeruginosa biofilm provides an ideal scenario to share virulence genes through 
45 HGT. Therefore, understanding how to remove or control biofilm, and therefore limit potential HGT 46 
47 of virulence genes, is an important and active research field. Various molecules have been identified 
48 
49 as having both antibiofilm and anti-virulence effects. For example, the flavanol quercetin [69], ZnO 
50 nanoparticles [70], garlic [71] and cinnamon oil [72] all have been shown to have both antibiofilm and 
51 
52 anti-virulence effects. The genetic links between antibiofilm and anti-virulence activity has also been 
53 
54 explored, for example, in a typA (a GTPase) mutant that has demonstrably lower virulence and 
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3 A more targeted approach to biofilm control relies on the ability for bacterial cells to revert from 
4 
5 biofilm to planktonic (unattached and free-floating), causing dispersal of cells. However, this process 
6 
7 is not easy, due to the cementing of cells into complex 3D structures which form biofilm [74]. 
8 Dispersins are molecules that trigger cell dispersal. For example, the signalling molecules nitric oxide 
9 
10 (NO) [75], succinate, glutamate, glucose [76] and the dendrimer FD2 [77] have all been shown to 
11 
12 trigger enhanced dispersal of P. aeruginosa cells from biofilm. Innovations in electrochemical 
13 engineering may also provide one avenue for researchers to find new dispersins. In 2018, Robb 
14 
15 demonstrated the use of pyrolytic graphite electrodes to assess potential dispersal-inducing 
16 
17 properties of 2-aminoimidazole (2-AI) [78]. Such analytical technologies may enable microbiologists 





23 Another targeted approach for biofilm control is the use of depolymerase, enzymes which are able to 
24 
25 breakdown polymeric substances. Depolymerase produced by P. aeruginosa has been a topic of 
26 
27 research for decades [79], with much focus on bacteriophage-encoded depolymerases [80, 81]. It is 
28 believed that phage with depolymerase can degrade extracellular polymeric substances (EPS - the 
30 ‘cement’ of the biofilm), gaining easier access to host receptors. This ability to degrade the EPS also 
31 
32 means the phage are likely able to infect cells within a biofilm more efficiently. For example, PT-6, a 
33 P. aeruginosa-infecting phage was able to reduce viscosity of four different alginate polymers by two- 
35 thirds within 15 minutes [82]. A recent review found 160 putative depolymerases from 143 phage, 
36 
37 including sialidases, levanases, xylosidases, dextranases, hyaluronidases, peptidases as well as 
38 pectate/pectin lyases [83]. These represent potential anti-virulence strategies for the reduction of 
40 prevention of P. aeruginosa biofilm formation. Whilst there is a lack of literature describing the impact 
41 
42 of antibiofilm measures on HGT, given the potential for HGT in biofilm (as discussed earlier), 
43 
44 controlling biofilm should be considered a potential intervention strategy for the potential of P. 
45 aeruginosa to acquire virulence genes (and other genetic material). This is particularly important in 46 





52 2.2 Controlling Quorum Sensing 
53 
54 Quorum sensing is well known to be important in P. aeruginosa biofilm development [84], which as 
55 described previously, can be considered an important enabler for HGT. Therefore, strategies to control 
56 
57 or reduce QS, and therefore reduce biofilm formation, may provide an indirect strategy for reducing 
58 
59 HGT. P. aeruginosa has at least four quorum-sensing signalling networks, Las, Rhl, Pqs and Iqs [85]. 
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3 The presence of QS molecules is associated with the production of extracellular DNA [86] and elevated 
4 
5 rates of horizontal gene transfer (HGT) [87]. A study by Rossmann, Racek [88] found that high 
6 
7 concentrations of the universal AI-2 compound in an already established biofilm promoted the release 
8 of phage capable of infecting other bacteria, increasing their virulence. In E. coli, transfer of antibiotic 
9 
10 resistant plasmids can be enhanced by the presence of autoinducers, however, QS inhibitors were 
11 
12 able to inhibit the transfer [89]. Various QS inhibitors have been demonstrated to block P. aeruginosa 
13 QS molecules. A synthetic derivative of a naturally occurring furanone has demonstrated antagonistic 
14 
15 activity against P. aeruginosa QS, increasing susceptibility of biofilm to antibiotics and increased 
16 
17 clearance in a mouse model [90]. The compound meta-bromo-thiolactone (mBTL), has also 
18 demonstrated inhibition of virulence factor production in P. aeruginosa, in addition to inhibiting 
19 
20 biofilm formation by partially inhibiting LasR and RhlL [91]. Other compounds such as the essential oil 
21 
22 6-Ginerol, produced by fresh ginger, has similarly demonstrated QS inhibition [92]. Furthermore, 
23 presence of QS inhibitors has been shown to supress the CRISPR-Cas9 system in P. aeruginosa, making 
24 
25 the bacterial cell more prone to death resulting from phage infection [93]. These are only an example 
26 
27 of the wide range of research currently ongoing to understand the impact of QS in P. aeruginosa and 
28 many other microorganisms, a new and fast paced field [94]. Whilst specific literature describing the 
30 impact of QS control on HGT of virulence genes is lacking, it is clear that QS control has huge potential 
31 





37 2.3 Molecular Diagnostics 
38 
39 Rapid genomic or metagenomic sequencing from patient samples should soon deliver a future where 
40 key features such as species diversity antibiotic sensitivity and virulence gene complement can be 
41 
42 determined in a clinically relevant timescale to guide appropriate and specific intervention strategies 
43 
44 including patient isolation and specific antibiotic regimens. Rapid, real-time outbreak analysis and in 
45 silico resistome characterisation will lead to more targeted and thus more effective antibiotic 
46 
47 administration that will also reduce the diversifying selection on microbial communities that is 
48 
49 imposed by inappropriate antibiotic administration. The potential for Nextgen genomic sequencing to 
50 deliver epidemiologically useful information within a clinically useful timeframe was first 
51 
52 demonstrated during an outbreak of Staphylococcus aureus in a paediatric setting in Cambridge, UK 
53 
54 in 2012 [95]. The potential for in silico resistome analysis as a tool to determine the antibiotic 
55 sensitivity of P. aeruginosa has been successfully demonstrated in two separate studies [53, 96] and 
56 
57 NGS is becoming a commonly used tool in retrospective analyses of P. aeruginosa outbreaks, for 
58 
59 example in a 2014 study tracing an outbreak due to an XDR ST111 clone in the United Kingdom [97]. 
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3 Therefore, there do not seem to be any significant barriers (except cost) to the routine use of genome 
4 
5 sequencing in hospital laboratories for outbreak control and antibiotic prescribing purposes. With few 
6 
7 therapeutic options for treating some P. aeruginosa infections, rapid information on antibiotic 
8 sensitivity of an individual isolate could be crucial and it could be used to guide and minimise 
9 
10 inappropriate use of new antibiotics as they are developed. 
11 
12 
13 The use of new agents such as therapeutic antibodies and antimicrobial peptides, perhaps co- 
14 
15 administered with antibiotics, could also be effectively targeted for the control of “high-risk” P. 
16 
17 aeruginosa genotypes based on rapid genomic profiling in hospital settings. 
18 
19 
20 2.4 Controlling environmental conditions likely to encourage HGT - photocatalysis 
21 
22 AMR is increasingly recognised as a problem outside of the clinic with many organisms acquiring and 
23 transmitting resistance and virulence genes within and between environmental, agricultural and 
24 
25 animal (including human) reservoirs. Thus, control of key human pathogens such as P. aeruginosa in 
26 
27 the environment could play a major role in reducing HGT of resistance and virulence loci. 
28 
29 
30 Wastewater is considered a hotspot for horizontal gene transfer [98]. Overuse and potential misuse 
31 
32 of antibiotics in farming, industry and medicine (both human and veterinary) as well as irresponsible 
33 use of pollutants such as heavy metals and disinfectants have resulted in the inevitable discharge into 
35 waste water [99]. These conditions cause cellular stress, which alongside high bacterial numbers (and 
36 
37 subsequent populations of bacteriophage) and biofilm formation [100] have led to a uniquely blurred 
38 boundary between the human and natural world where HGT is readily facilitated. Isolates of P. 
40 aeruginosa, is a common member of the wastewater community, have demonstrated an increase in 
41 
42 QS production linked with potential virulence and biofilm formation [101]. More generally, transfer of 
43 
44 antimicrobial resistance genes (ARG) in wastewater has become a dominant line of research [102], 
45 with suggestion that bacteria gaining ARGs via phage may also have an increased capacity for virulence 46 
47 [103]. Therefore, interventions that target conditions within aquatic environments that promote HGT 
48 
49 should be a priority. 
50 
51 
52 Advanced treatment technologies such as photocatalysis have demonstrated efficiency at removing 
53 
54 contaminants from wastewater [102]. Over recent years, photocatalysis, a relatively simple, yet 
55 efficient technique of mineralizing organic contaminants to carbon dioxide and water without the 
56 
57 production of secondary pollutants, has gained popularity as a safe, cheap and sustainable method 
58 
59 for water decontamination [104, 105]. Titanium dioxide (Titania, TiO2) is the most studied 
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3 photocatalytic material for decontamination, depollution and disinfection processes [105, 106], killing 
4 
5 P. aeruginosa (and other bacteria) through the generation of radical oxygen species [107, 108, 109, 
6 
7 110], and can be favoured over other antimicrobial active substances due to its long-term 
8 antimicrobial action [111]. In addition to killing bacteria, photocatalysis has also been shown to break 
9 
10 down viruses, and a wide variety of organic materials [112, 113, 114]. All of these properties target 
11 
12 and reduce the factors that can increase HGT (large number of bacterial cells, pollutants and biofilm). 
13 
14 
15 Despite the obvious benefits of such an antimicrobial material, fundamental questions relating to the 
16 
17 effect of photocatalytic coatings on the microbiology of water have been raised in the literature. 
18 Critically, some advanced treatment technologies do not provide a rapid bacterial kill, and will create 
19 
20 conditions likely to cause cellular stress and potentially leading to the cell SOS response, encouraging 
21 
22 horizontal gene transfer. 
23 
24 
25 3. Conclusion 
26 
27 Pseudomonas aeruginosa occupies a huge variety of environmental niches being a ubiquitous in many 
28 soils and watercourse habitats. These isolates are frequently indistinguishable from those colonising 
30 and infecting humans. The species diversity and genome plasticity reflects this – the species has a very 
31 
32 small core genome of a few hundred genes representing 1% of the species genes discovered thus far. 
33 Approximately half of the genes found in P. aeruginosa have only been seen in one isolate. A 
35 significant proportion of this pan- genome especially that related to antibiotic resistance is mobile, 
36 
37 present on elements such as plasmids, transposons and insertion sequences however the 
38 chromosome itself is also subject to high rates of recombinational change through HGT. The rapid 
40 detection and characterization of globally disseminated “High Risk” genotypes (clones) that are 
41 
42 particularly associated with enhanced virulence and MDR, XDR and PDR resistance to antibiotics, 
43 
44 through molecular diagnostics should enable more targeted treatments based on inferred antibiotic 
45 sensitivity from genome data or where no antibiotic is available, treatment with other agents in 46 
47 development such as therapeutic monoclonal antibodies or antimicrobial peptides. Anti-virulence 
48 
49 molecules that interfere with inter-cell quorum sensing and signalling or approaches that destroy 
50 mixed strain and species biofilms where gene exchange occurs at high frequency represent future 
51 
52 approaches for limiting the proliferation of P. aeruginosa genes for antibiotic resistance and virulence 
53 
54 that represent an increasing threat to human health. 
55 
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3 Figure 1. Genomic diversity of P. aeruginosa clinical isolates. (A) Phylogenetic tree of P. 
4 aeruginosa clinical isolates. Phylogenetically related ST groups with >7 members are shown 
6 in different colors. The prevalent lineages constitute 52% of all strains analyzed. ST groups 
7 that have only 1 member are delineated in grey, while black denotes phylogenetic lineages 
8 with 2 to 6 members. The phylogenetic locations of the common laboratory strains PAO1, 
9 PA14, and PA7 are marked in black for reference, while the 4 nonclinical isolates are 
11 labelled with small black asterisks. Figure reprinted from Van Belkum et al. mBio. 2015 [36]. 
12 
13 Figure 2. Summary of key virulence determinants and factors important for biofilm 
14 formation produced by Pseudomonas aeruginosa. Reproduced from Diggle and Whiteley, 
15 2019 [110]. 
17 
18 Figure 3. The hierarchy quorum sensing network in Pseudomonas aeruginosa. Reproduced 
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